Você procurou por: tirkadi (Maltês - Inglês)

tirkadi u tbatti
85% (37%)

qisu qed terġa tirkadi.
a relapse.

sklerożi multipla li tirkadi
relapsing multiple sclerosis

sklerożi multipla li tirkadi u tbatti
relapsing- remitting multiple sclerosis

sklerożi multipla li tirkadi u tbatti:
in this leaflet:

sklerożi multipla li tirkadi-tbatti (rr-ms)
relapsing-remitting multiple sclerosis (rr-ms)

pazjenti dijanjostikati bi sklerosi multipla (ms) li tirkadi.
patients diagnosed with relapsing multiple sclerosis (ms).

tortikollis (tirkadi mil-linja bażi), perverżjoni tat-togħma
torticollis (worsening from baseline), taste perversion

tecfidera jintuża għal kura ta’ sklerożi multipla (ms) li tirkadi u tbatti.
tecfidera is used to treat relapsing-remitting multiple sclerosis (ms).

rebif hu indikat għall-kura ta’ pazjenti bi sklerożi multipla li terġa tirkadi.
rebif is indicated for the treatment of relapsing multiple sclerosis.

eżatt wara injezzjoni l-muskoli tiegħek jistgħu jinħassu stirati jew dgħajfa ħafna – bħal qisu qed terġa tirkadi.
just after an injection, your muscles may feel tense or very weak – as though you are having a relapse.

għal sklerożi multipla li tirkadi u tbatti l-effikaċja tat-terapija ġiet murija għall-ewwel sentejn.
for relapsing-remitting ms, efficacy has been demonstrated for therapy for the first two years.

pazjenti bi sklerożi multipla li tirkadi u tbatti b’żewġ episodji ta’ rkadar jew iktar fl-aħħar sentejn.
patients with relapsing remitting multiple sclerosis and two or more relapses within the last two years.

l-analiżi miġbura kkontrollata bi plaċebo ġiet ibbażata fuq 2047 pazjent bi sklerożi multipla li tirkadi, ikkurati b'teriflunomide darba kuljum.
the placebo-controlled pooled analysis was based on 2047 patients with relapsing multiple sclerosis treated with teriflunomide once daily.

hemm tagħrif tal- follow-up taħt kundizzjonijiet kliniċi kontrollati għal pazjenti li għandhom sklerożi multipla li tirkadi u tbatti sa 5 snin u għal pazjenti li għandhom sklerożi multipla progressiva sekondarja sa 3 snin.
there are follow-up data under controlled clinical conditions for patients with relapsing-remitting multiple sclerosis for up to 5 years and for patients with secondary progressive multiple sclerosis for up to 3 years.

effikaċja klinika bl-għoti taħt il-ġilda ta’ bortezomib f’pazjenti b’majeloma multipla li tirkadi/refrattorja
clinical efficacy with subcutaneous administration of bortezomib in patients with relapsed/refractory multiple myeloma

persuni b’ ms li tirkadi u tbatti jkollhom attakki kull tant żmien jew rikaduti li matulhom is- sintomi jmorru għall- agħar b’ mod notevoli.
people with relapsing-remitting ms have occasional attacks or relapses during which symptoms become noticeably worse.

għall-pazjenti bi sklerożi multipla li tirkadi u tbatti hemm tagħrif meħud wara l-bidu tal-kura taħt kundizzjonijiet kliniċi kkontrollati sa 5 snin u għal pazjenti bi sklerożi multipla progressiva sekondarja hemm tagħrif sa 3 snin.
there are follow-up data under controlled clinical conditions for patients with relapsing-remitting ms for up to 5 years and for patients with secondary progressive ms for up to 3 years.